Status:
RECRUITING
The Efficacy Evaluation of Buckwheat Husk Extract on Cardiovascular Disease Risk Factors
Lead Sponsor:
TCI Co., Ltd.
Conditions:
Cardiovascular Diseases
Eligibility:
All Genders
20-65 years
Phase:
NA
Brief Summary
To assess the efficacy evaluation of buckwheat husk extract on cardiovascular disease risk factors
Detailed Description
This is a double-blind and randomized study. Subjects are informed to consume the samples every day for 2 months. The clinical diagnosis item of cardiovascular disease is evaluated by the doctor.
Eligibility Criteria
Inclusion
- 20 to 65-year-old males or non-pregnant females who are willing to sign the subject's consent.
- The systolic blood pressure is 121-139 mmHg and the diastolic blood pressure is between 81-89 mmHg.
- Those who are not pregnant and are willing to cooperate with contraception during the trial period.
- No history of organ transplantation, epilepsy or convulsions, liver or kidney disease, malignant tumor, endocrine disease, mental disease, alcohol or drug abuse, or other major organic diseases (according to medical history).
Exclusion
- Pregnant women.
- People with a history of organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental illness, alcohol or drug abuse, and other major organic diseases (according to medical history).
- No person has undergone major surgery.
Key Trial Info
Start Date :
November 24 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04490720
Start Date
November 24 2021
End Date
February 28 2026
Last Update
January 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 114